SOUTH SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE), today announced that Stephen A. Sherwin, M.D.,
chairman and chief executive officer of Cell Genesys, will present a company
update at the Banc of America Securities Health Care Conference in Las Vegas,
NV that will be broadcast live over the internet on Friday, May 21st at 8:00
a.m. PDT.
The webcast will be available on the Investor Relations section of the
Cell Genesys website, http://www.cellgenesys.com. If you are unable to listen to the
live webcast, it will be archived on the site for at least 48 hours following
the presentation. To access the replay, go to the Investor Relations section
of the website.
Cell Genesys is focused on the development and commercialization of novel
biological therapies for patients with cancer. The company is pursuing three
cancer product platforms -- GVAX(R) cancer vaccines, oncolytic virus therapies
and antiangiogenesis therapies. Clinical trials of GVAX(R) vaccines are under
way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma.
Clinical programs of oncolytic virus therapies include CG7870 for prostate
cancer. Preclinical studies are in progress for additional GVAX(R) cancer
vaccines, oncolytic virus therapies and antiangiogenesis therapies for
multiple types of cancer. Cell Genesys' majority-owned subsidiary, Ceregene,
Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also
continues to hold an equity interest in its former subsidiary, Abgenix, Inc.,
an antibody products company. Cell Genesys is headquartered in South San
Francisco, CA and has manufacturing operations in San Diego, CA, Hayward, CA
and Memphis, TN. For additional information, please visit the company's
website at http://www.cellgenesys.com.
Statements made herein about Cell Genesys and its subsidiaries, other than
statements of historical fact, including statements about the nature of
product pipelines are forward-looking statements and are subject to a number
of uncertainties that could cause actual results to differ materially from the
statements made, including risks associated with the success of research and
development programs, the success of clinical trials, the regulatory approval
process, competitive technologies and products, patents and additional
financings. For information about these and other risks which may affect Cell
Genesys, please see the company's Annual Report on Form 10-K dated March 4,
2004 as well as Cell Genesys' reports on Forms 10-Q and 8-K and other reports
filed with the Securities and Exchange Commission.
Contact: Jennifer Cook Williams
Director, Corporate Communications
and Investor Relations
650-266-3200
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
Jennifer Cook Williams, Director, Corporate
Communications and Investor Relations of Cell Genesys, Inc.,
+1-650-266-3200
|
